Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.66 |
| ▸ | TAS1R2 | Q8TE23 | 13/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161659 | 0.82 | TAS1R3 (0.62) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL703140 | 0.79 | TAS1R3 (0.73) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL700840 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL702725 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL700841 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL27734667 | 0.77 | TAS1R3 (0.66) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL27734743 | 0.77 | TAS1R3 (0.66) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL22222488 | 0.76 | PKM (0.83) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL5752877 | 0.76 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM | |
| SCHEMBL5924001 | 0.76 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | TAS2R10, TAS2R50, TAS2R8 | TAS1R3 27/4885TAS1R1 23/4885TAS1R2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.